Replies to post #241076 on Biotech Values

[DewDiligence]

ANNX completes phase-2 enrollment for dry AMD—results in 1H23:

https://www.globenewswire.com/news-release/2022/04/07/2418284/0/en/Annexon-Biosciences-Completes-Enrollment-in-ARCHER-Phase-2-Trial-of-Novel-C1q-Inhibitor-ANX007-in-Patients-with-Geographic-Atrophy.html

Treatment of dry AMD is a major unmet need, and ANNX is currently trading at a market cap that is roughly half its cash on hand. (No position.)